Roshal Patel

@roshalp

Radiation Oncology Resident @MSK_RadOnc

Katılım Haziran 2013

118 Takip Edilen88 Takipçiler

Roshal Patel retweetledi

Brandon Imber@brandon_imber·20 Haz

Double trouble! Congrats to @RoshalPatel on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! @MSK_RadOnc @MSKCancerCenter #18ICML

English

3.2K

Roshal Patel retweetledi

Brandon Imber@brandon_imber·20 Haz

Beyond proud of our @MSK_RadOnc hematology research team! Exciting research at the forefront of all aspects of #18ICML!! Hopefully the Lago view makes up for all the hard work 😉 @MSKCancerCenter

English

1.5K

Roshal Patel retweetledi

Kathryn Ries Tringale@KathrynTringale·19 Haz

Amazing work @fregonese_bea presenting our initial results on financial toxicity and decision regret in #aya #hodgkinlymphoma survivors. There’s still time for patients to fill out the survey: bit.ly/3SLZ0ke

English

1.3K

Roshal Patel@roshalp·19 Haz

#ICML2025 @brandon_imber

Ajay Major, MD, MBA@majorajay

We stan bridging RT before CAR! #18ICML - 116 pts with comprehensive RT to all PET avid sites - higher RT dose = less post-CAR G3+ CRS - higher LDH after RT = more G3+ CRS/ICANS Who else is using multisite bridging RT before CAR? #lymsm #tcellrx

QME

156

Roshal Patel retweetledi

Ethan Ludmir MD@ebludmir·4 Mar

V relevant given newly-finalized guidance from @FDAOncology, these are potentially actionable changes in trial eligibility criteria to address age disparities. Highlighted in @ScienceMagazine science.org/content/articl…. Excellent work by @roshalp & co! @cd_fuller @geriradonc

Roshal Patel@roshalp

Eligibility criteria in #cancer clinical trials that exclude patients with prior malignancies may independently contribute to age disparities @ebludmir @Cancers_MDPI mdpi.com/2072-6694/14/4…

English

Roshal Patel@roshalp·28 Şub

These data support recent ASCO and FDA guidelines suggesting that patients with previous cancers with limited potential to affect safety/efficacy assessment should be included in trials asco.org/research-data/…

English

Roshal Patel@roshalp·28 Şub

-Prior malignancy exclusion criteria are widely utilized among cancer trials -Longer exclusionary timeframes may worsen age disparities affecting older patient enrollment into trials -Broadening eligibility criteria can improve generalizability and increase trial enrollment

English

Roshal Patel@roshalp·28 Şub

Eligibility criteria in #cancer clinical trials that exclude patients with prior malignancies may independently contribute to age disparities @ebludmir @Cancers_MDPI mdpi.com/2072-6694/14/4…

English

Keşfet

@RoshalPatel @MSK_RadOnc @MSKCancerCenter @fregonese_bea @brandon_imber @FDAOncology @ScienceMagazine @geriradonc